2024
Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor
Brösecke F, Pfau A, Ermer T, Dein Terra Mota Ribeiro A, Rubenbauer L, Rao V, Burlein S, Genser B, Reichel M, Aronson P, Coca S, Knauf F. Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor. Scientific Reports 2024, 14: 11323. PMID: 38760468, PMCID: PMC11101424, DOI: 10.1038/s41598-024-61808-7.Peer-Reviewed Original ResearchConceptsIL-16 levelsIL-16Dialysis patientsCardiovascular eventsConcentrations of IL-16Kidney failureUremic toxinsCardiovascular diseaseCompared to healthy individualsPlasma oxalate concentrationActivated immune cellsAssociated with cardiovascular diseaseIL-16 concentrationCytokine IL-16Cardiovascular risk factorsNo significant associationPlasma oxalateInflammatory markersImmune cellsCytokine concentrationsInterleukin-16US patientsCohort 1Cardiovascular outcomesHealthy individuals
2022
Bioaccumulation of Blood Long-Chain Fatty Acids during Hemodialysis
Liu T, Dogan I, Rothe M, Reichardt J, Knauf F, Gollasch M, Luft F, Gollasch B. Bioaccumulation of Blood Long-Chain Fatty Acids during Hemodialysis. Metabolites 2022, 12: 269. PMID: 35323712, PMCID: PMC8949028, DOI: 10.3390/metabo12030269.Peer-Reviewed Original ResearchChronic kidney diseaseRed blood cellsLong-chain fatty acidsHD treatmentUpper limbEnd-stage renal disease patientsPeripheral tissue perfusionSingle HD treatmentRenal disease patientsFatty acid statusVenous blood samplesFatty acidsCardiovascular eventsESRD patientsHD patientsKidney diseaseDisease patientsVenous bloodHemodialysis treatmentAcid statusUremia altersBlood samplesTissue perfusionLCFA levelsFatty acids n